Burden of disease and epidemiology
The incidence of bacterial meningitis varies throughout the world. In Western settings, the incidence is 1-2 cases per 100,000, whereas it can reach 1,000 cases per 100,000 in the Sahel region of Africa (Figure 1 ) [1] [2] [3] . A huge reduction in incidence has been seen over the last few decades, largely secondary to the introduction and widespread use of conjugate vaccines 1, [3] [4] [5] [6] . Conjugate vaccines have a protein attached to purified bacterial capsular polysaccharide. This elicits a more robust and sustained immune response, especially in young children. Table 1 gives an overview of vaccines currently available to prevent bacterial meningitis. Much of the reduction in incidence has been in children under one year 1, 5 . Similarly the largest reductions in meningitis-associated mortality, globally, have been seen in children under five years of age, with a 43% decrease in neonates and a 54% reduction in children aged between one and 59 months 
Streptococcus pneumoniae
Pneumococcus is the commonest cause of bacterial meningitis in adults in much of the world 1, 5, 8, 9 . There are over 90 antigenically different serotypes of S. pneumoniae as determined by the polysaccharide capsule -the target for all currently licensed vaccines.
Pneumococcal conjugate vaccines (PCV) have been used for the last 15 years. PCV7 targeted seven pneumococcal serotypes and more recently PCV10 and PCV13 (covering ten and thirteen serotypes respectively) were licensed in the US and Europe. The polysaccharide vaccine, PPV23, covers 23 serotypes. Until recently, conjugate vaccines were largely used only in children but a recent placebo-controlled trial in people 65 years of age and older has shown good efficacy of PCV13 in preventing vaccine-type pneumococcal pneumonia, non-bacteraemic pneumonia and invasive pneumococcal disease, with vaccine efficacies of 45·6%, 45%, and 75% respectively 10 . Although the 5 majority of studies on the immunogenicity of pneumococcal vaccines are non-comparative, there is some evidence that PCV is more immunogenic 11 . The conjugate vaccines also produce substantial herd immunity, when vaccination of part of the population provides protection for non-vaccinated individuals. . Recent large studies have shown dramatic reductions of disease caused by vaccine serotypes in both vaccinated and unvaccinated populations [12] [13] [14] [15] .
Since conjugate vaccines were first introduced serotype replacement has been observed. This is an increase in the incidence of disease and/or asymptomatic carriage caused by non-vaccine serotypes. [16] [17] [18] [19] Despite this the overall incidence of invasive pneumococcal disease has dropped. A meta-analysis from Europe, the Americas and Australia confirmed a sustained reduction in the incidence of pneumococcal meningitis in children seven years post-vaccination (risk ratio for meningitis was 0·40, (95% CI 0·25-0·64). There was a similar, but smaller, reduction in adults with a relative risk of meningitis in 18-49 year olds of 0·61, (95% CI 0·4-0·95) seven years after vaccination.
For older adults aged 50-64 years, there was a decrease in meningitis caused by the vaccine serotypes but this was offset by a significant increase in non-vaccine serotype disease (RR 2·83 95%
CI 1·46-5·47) 20 . Mathematical models have predicted a substantial reduction in disease following the introduction of PCV13, even taking serotype replacement into account 21, 22 . Recent observational studies confirm this with a 32% reduction in invasive pneumococcal disease following the introduction of PCV13, but a 25% increase in non-PCV13 serotypes 23 .
Neisseria meningitidis
Meningococci are categorised into 13 serogroups; five (A, B, C, W135, and Y) are responsible for most cases of invasive disease. Serogroup B is the commonest strain across Europe, including
England and Wales where it is responsible for the majority of cases 24, 25 . Serogroup Y is predominant in the USA 26 and the second most common in parts of Europe
27
. Recently there has been a rise in serogroup W135 in the UK, which has been shown to be linked with a South American clone.
Disease caused by this clone is associated with a higher mortality as they are part of the more deadly ST11 clonal complex (or cc11) 28 . The same clonal complex is responsible for recent outbreaks of meningococcal C disease amongst gay men 29, 30 . Serogroup C was previously responsible for most meningococcal disease in Western countries, but incidence has markedly declined following the introduction of the meningococcal C conjugate vaccine. In the Netherlands, incidence has declined from 4·5/100,000 in 2001 to 0·6/100,000 in 2012
. Similar results have been seen in other countries 5, 14 . 
Pathogenesis
Many aspects of the pathogenesis of bacterial meningitis have yet to be understood; however, there are four main processes: colonisation, invasion into the blood stream, survival in the bloodstream and, entry into the subarachnoid space. The subsequent inflammation and neurological damage is caused by a combination of bacterial and host factors. . Direct entry from the nose through dural defects is also possible.
Entry into the central nervous system and inflammation
Due to a lack of host defences in the subarachnoid space, bacteria multiply relatively unhindered. 
Genetic predisposition
Several studies have suggested a genetic predisposition to bacterial meningitis, with most related to deficiencies that affect the complement system. In particular, C2 deficiency was found in 58% of 
The role of neuroimaging
The use of neuroimaging before LP has generated considerable debate with some recommending cerebral imaging is performed before LP for all patients. However this has been associated with delays in antibiotic administration, reduced likelihood of identifying a pathogen and an increase in . The worldwide emergence of antimicrobial resistance, especially against S. pneumoniae, affects the choice of empirical treatment in many countries. This is especially important in the poorer regions of the world where newer antibiotics may not be available or affordable. Table 3 gives recommendations for empirical antibiotics.
Antimicrobial resistance
Penicillin-resistant pneumococci have been reported from all parts of the world 91 and have been associated with an increase in mortality
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. Vancomycin is widely recommended when penicillinresistant pneumococci are possible, but due to the fact that it crosses the blood brain barrier poorly it should be used in conjunction with another antimicrobial, often a cephalosporin. .
Fluoroquinolones may be good alternatives in the era of penicillin-resistant pneumococci.
Experimental mouse models have shown moxifloxacin to be equivalent to cephalosporins . Without evidence from comparative therapeutic trials, these agents should be used with caution and only when other better tested agents cannot be used either because of resistance, patient intolerance or allergy.
Efforts should be made to identify local patterns of antibiotic resistance to determine the optimal empirical treatment for each geographic area. In the UK, where there is a low prevalence of penicillin-resistance, third-generation cephalosporins (cefotaxime or ceftriaxone) remain the empirical choice. However, many parts of the world have penicillin-resistant pneumococci (MIC ≥0·12µg/ml) with rates of approximately 25% in the United States and parts of Europe (e.g. Spain,
Croatia, Romania) and over 50% in Asia; 100% of isolates were found to be penicillin resistant in
Vietnam and Thailand but numbers were small (n=6 and 1 respectively) [101] [102] [103] . In these areas vancomycin (with or without rifampicin) should be given in addition to a third-generation cephalosporin 104 . Alternatives are listed in table 3.
Antibiotic resistance in meningococci is rare 27 although decreased susceptibility to penicillin has been particularly associated with some serogroups, especially C and W135
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.
Duration of therapy
There is limited trial evidence to guide how long to treat adults with bacterial meningitis. Using shorter courses of antibiotics can reduce hospital stay and costs and may also reduce the risk of adverse events such as nosocomial infections. Paediatric studies have shown that shorter courses are safe and effective 109, 110 . A meta-analysis, looking at all causes of bacterial meningitis in children, found a short (4-7 days) course to be as efficacious as a long (7-14 days) course of antibiotics;
unfortunately, no adult studies could be identified for inclusion 111 . 
Adjunctive therapies
Even in the presence of a susceptible organism and appropriate antibiotics, mortality in bacterial meningitis is high, around 10-30% in industrialised nations 4,8,113,116-119 and nearer 50% in many poorer nations [120] [121] [122] .The high number of deaths, despite apparently appropriate treatment, is thought to be due to the inflammatory processes described earlier. Efforts have, therefore, focused on identifying useful adjunctive therapies which might reduce inflammation and brain oedema.
Corticosteroids
Following several paediatric studies 123 , a large multi-centre European randomised controlled trial in adults showed a significant reduction of both an unfavourable outcome and death in patients who were treated with dexamethasone compared to placebo (RR 0·59 and 0·48 for unfavourable outcome and death respectively), most striking for the subgroup of patients with pneumococcal meningitis 124 . Subsequent studies carried out in adults in Malawi and Vietnam failed to reproduce the European findings 122, 125 , although there was a better outcome (significant reduction in the risk of death at 1 month and risk for death or disability at 6 months) for patients in Vietnam with confirmed bacterial meningitis. A meta-analysis of individual patient data (n=2029) suggested the differences were not due to the high rates of HIV and tuberculosis in these countries 126 . This meta-analysis concluded that there were no subgroups that might benefit from adjunctive dexamethasone, although post-hoc analyses did suggest there might be some benefit in HIV negative adults and a lower rate of hearing loss amongst all survivors.
Another meta-analysis of 25 studies, in both adults and children, showed a small reduction in hearing loss in adults treated with corticosteroids compared with placebo (16% versus 22% RR 0·74, 95%CI 0·56-0·98) but no difference in mortality
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. A subgroup analysis demonstrated a slight decline in mortality in all patients with pneumococcal meningitis (RR 0·84 95% CI 0·72-0·98) with no effect on H. influenzae or meningococcal meningitis (although numbers in these groups were very small).
It should be noted that this benefit did not remain when a random-effects model was used (which may have been more appropriate given the heterogeneity of the studies (I 2 47%))
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Both these meta-analyses compared very diverse studies and populations including children and adults, high and low socio-economic status and differences in co-morbidities. This is reflected in the heterogeneity of the analyses and possibly accounts for the conflicting conclusions. However, there needs to be a balance between the risks and potential benefits of corticosteroid use. Overall, it seems that corticosteroids may offer a small benefit in adults with regard to reducing hearing loss and may have a slightly lower mortality in pneumococcal meningitis. In most studies there is no increase in side-effects when corticosteroids were given in comparison to placebo. It is, therefore, recommended to give steroids to all adults with suspected bacterial meningitis in resource rich countries. Although the meta-analyses did not demonstrate a difference between countries of high and low income, there was considerable heterogeneity and in lower income countries the benefits are probably less pronounced; therefore, corticosteroids are not recommended in this group.
The dose of corticosteroids differs between trials, but the one that was used in the large Dutch trial is 10 mg of dexamethasone given four times a day . Sub-group analyses in both meta-analyses showed no statistical differences in terms of mortality when corticosteroids were given before or with antibiotics compared with when they were given afterwards 123, 126 . There were differences when hearing loss was the outcome of interest and indeed the effect size was bigger in the group who received corticosteroids after antibiotics compared with the group who . However, a recent randomised controlled trial was stopped early due to an increased risk of death in patients in the intervention arm
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. It is unlikely that hypothermia or glycerol will be widely implemented without adaptation and further controlled trials.
Prognosis and sequelae
Features associated with a poor prognosis include older age, reduced conscious level, tachycardia, a CSF leukocyte count of less than 1000 x 10 9 cells/ml, reduced platelet count 
The Future

New vaccines
Many of the pneumococcal vaccines in development are focussing on protein-based strategies (rather than being based on the capsular polysaccharide), to be given either in addition or as a replacement to conjugate vaccines. This may allow pan-serotype protection and eliminate the problem of serotype replacement. Several early phase studies have been conducted, one of which (combining pneumolysin toxoid and histidine triad protein D, a pneumococcal surface protein thought to be involved in complement inhibition) has recently reported good evidence of immunogenicity with an acceptable safety profile in both younger and older adult cohorts [130] [131] [132] .
The search for a widely effective vaccine against meningococcal serogroup B has been difficult because of the poorly immunogenic capsule. Vaccines were developed that targeted sub-capsular proteins (see figure 3 ) and were used with some success in epidemics in Norway, Cuba, Brazil, New
Zealand, and France [133] [134] [135] . However, they were poorly immunogenic in young children and strain specific, and so could not be rolled out on a larger scale. Using a novel genome sequencing method, 
Author Contributions
FM performed the initial literature search and drafted the first version. All authors then contributed to further drafts and approved the final submitted version. SP gave specific input to the pathogenesis section and designed figure 2 and 3.
Conflicts of Interest
All authors disclose no conflicts of interest. 
